About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT04240496

Clinical and Genetic Influencing Factors on Clozapine Pharmacokinetics

Clozapine (Clz), an atypical antipsychotic, is the reference medication for patients with treatment-resistant schizophrenia. Due to the high inter-individual variability of its pharmacokinetics and it...

Lead sponsor: University of Monastir•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Monastir

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Schizophrenic patients receiving clozapine
•Good adherence to the treatment (clozapine)

Exclusion Criteria

•Patients who were co-prescribed drugs that affected the pharmacokinetics of Clozapine.
•Patients who presented gastrointestinal disorders disturbing absorption of clozapine.

Related studies

Implementation of Onsite Rapid CYP2C19 Assay for Genotype Guided Dual Antiplatelet Therapy After Acute Ischemic Stroke

NCT06292117 · Ischemic Stroke, CYP2C19 Polymorphism

RECRUITINGPhase 4

Clozapine-related Immunodeficiency in Parkinsons Disease

NCT06634641 · Clozapine, Parkinson's Disease (PD), and more

Caffeine, CYPA12 and Resistance Training

NCT06610123 · CYP1A2 Polymorphism, Caffeine and Resistance Training

COMPLETEDPhase 4

Rivastigmine for the Treatment of Hypoactive Anticholinergic Delirium and CNS Depression Associated Mainly With Clozapine Poisoning.

NCT07545382 · Anticholinergic Delirium, Clozapine Poisoning, and more

The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCI

NCT03758248 · Antiplatelet Therapy, CYP2C19 Polymorphism

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 27, 2020Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment51

Start dateOct 2019

Last updatedJan 27, 2020

Condition

CYP1A2 Polymorphism CYP2C19 Polymorphism Clozapine Schizophrenia

Locations shown

Faculty of Medecine of Monastir

Monastir

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 27, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions